The Phase 3 trial involved 1,200 participants with mild to moderate Alzheimer. Patients receiving the drug showed 27% less cognitive decline than the placebo group.
The medication works by targeting amyloid plaques in the brain. These protein clusters are associated with Alzheimer progression.
Side effects were generally mild, with headaches and nausea being most common. Only 3% of participants discontinued treatment due to adverse effects.
Regulatory agencies will review the data later this year. If approved, the drug could become available to patients in early 2027.